We would like to thank Dr. Srinivas for his interest in our previous publication and his pertinent comments \[[@CR1]\].

First, we would like to describe the preparation and administration of GR007 in detail, which was not shown in our article. This process was very simple. The freeze-dried powder was diluted with isotonic saline to prepare GR007 intramuscular (IM) injection solutions of 1, 3, and 5 mL for doses of 30, 90, and 150 mg, respectively. The IM injection solutions were administered as a single injection within 3 min. We chose the gluteus maximus as the injection site because this region is free of major nerves and blood vessels. According to the volume of the IM injection, 2, 5, and 5 mL syringes were used for doses of 30, 90 and 150 mg, respectively. All the above information has been mentioned in our clinical trial protocol.

Dr. Srinivas's argument seems to be that for IM injections, the 5 mL volume of solution used in our study was infeasible. However, this issue had already been considered in the development of our protocol. Considering the characteristics of the Phase I study, one of our objectives was to assess the tolerability of the investigational drug on the premise of guaranteeing the safety of the subjects. When searching the literature, a number of articles have indicated that a volume of 5 mL is feasible for an IM injection to the gluteus maximus \[[@CR2]--[@CR4]\]. Moreover, this method of administering GR007 can minimize administration frequency and increase the compliance of the subjects. Furthermore, no sclerosis was found at the injection site during the administration of GR007 and no injection site response was observed in this study. Therefore, it is feasible to adopt this injection method. However, as we mentioned in our discussion section, the large volume of the injection may be a possible influencing factor that led to a disproportionate increase in the maximum concentration (*C*~max~).

We reported that for further studies, administration of GR007 would be once a day for multiple consecutive days; however, this may have caused Dr. Srinivas to misunderstand that this injection needs to be administered several times a day. We are extremely sorry for causing any misunderstanding regarding this issue.

It is well known that area under the concentration vs time curve (AUC) and *C*~max~ are common parameters used for the assessment of dose proportionality. Moreover, the statistical methods mentioned in our article are consistent with those released by the Center for Drug Evaluation (CDE) in China \[[@CR5]\]. Dr. Srinivas noted in his comment that for the case of dose proportionality of exposure with extended absorption and distribution stages, it would be somewhat misleading to judge it with the parameter of *C*~max~ \[[@CR1]\]. He also proposed that the AUC in the plateau phase of the absorption/distribution phase divided by the time duration might be a better parameter to examine it \[[@CR1]\]. However, when retrieving the literature, we did not find any relevant articles using this parameter. Moreover, how to define the *C* initial time point and ending time point lacks a unified standard. Therefore, this parameter lacks general applicability. Whether this parameter can be used in this case remains to be unverified. Therefore, we do not think that it is inappropriate to use *C*~max~ as a parameter for the assessment of dose proportionality.

Dr. Srinivas mentioned in his comment that keeping the same injection volume of GR007 in different dose groups is a better way to reduce the bias caused by different injection volumes \[[@CR1]\]. We agree with him, but as this approach may increase the cost and prolong the development timeline, it may be somewhat difficult for pharmaceutical enterprises to conduct.
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